BioSpace News Archive

Year

• 2005
• 2006
• 2007
• 2008
• 2009
• 2010
• 2011
• 2012
• 2013
• 2014
• 2015
• 2016
• 2017
• 2018
• 2019
• 2020
• 2021
• 2022
• 2023
• 2024
• 2025

Month

• January
• February
• March
• April
• May
• June
• July
• August
• September
• October
• November
• December

Day

• 1
• 2
• 4
• 5
• 6
• 7
• 8
• 9
• 10
• 11
• 12
• 13
• 14
• 15
• 17
• 18
• 19
• 20
• 21
• 22
• 24
• 25
• 26
• 27
• 28
• 29
• 30

• 

  Policy

  Fresenius SE Allegedly Ignored Hundreds of Bad Quality Tests at Plant in India

  The agency inspected the plant from May 15 to May 24, 2017, and observed that staffers at the plant were basically gaming the quality control system.

  December 28, 2017

   · 

  2 min read

   · 

  Mark Terry
• 

  Drug Development

  Johnson & Johnson’s Potential Depression Blockbuster Esketamine Shows Promise in Phase II Study

  The drug showed a significant, clinically meaningful and fast-acting improvement in depression symptoms compared to an intranasal placebo.

  December 28, 2017

   · 

  2 min read

   · 

  Mark Terry
• 

  Policy

  5 Biotechs Awaiting FDA Decisions in January 2018

  From 1997 through 2013, there was an average of 27 novel drugs approved in the U.S. per year.

  December 28, 2017

   · 

  2 min read

   · 

  Mark Terry
• 

  Business

  Keryx, Norwich Pharma Mutually Terminate Manufacturing Agreement

  The deal was originally inked on Jan 17, 2014‍.

  December 28, 2017

   · 

  1 min read
• 

  Genetown

  2 Small-Cap Biotechs Bestie Celgene is Cutting Back On

  Celgene has been unloading some of its shares in two of its investments, CRISPR Therapeutics and Atara Biotherapeutics.

  December 28, 2017

   · 

  3 min read

   · 

  Mark Terry
• 

  Policy

  Pharma Bro Shkreli’s Ex-Lawyer Convicted of Helping Him Defraud Pharma Firm

  Evan Greebel was found guilty by a federal jury in Brooklyn of charges he conspired to commit wire fraud and securities fraud.

  December 28, 2017

   · 

  1 min read
• 

  Deals

  China-Focused Life Science Investor Acquires 37% of NovaBay for $28M

  After the transaction, it will be NovaBay’s largest shareholder with 6.6 million shares, 37% of the total.

  December 28, 2017

   · 

  1 min read
• 

  Bio NC

  Drum Roll, Please…Introducing The 2018 Life Sciences Hotbeds

  The annual Hotbed Maps have guided professionals in their career paths all across the country and abroad.

  December 28, 2017

   · 

  1 min read

   · 

  Shaeffer Smith, Marketing Coordinator, BioSpace
• 

  Biotech Bay

  4 Top-Performing S&P 500 Biotech Stocks of 2017

  It was a pretty good year for the stock market, but how about for biotech stocks?

  December 28, 2017

   · 

  2 min read

   · 

  Mark Terry
• 

  Business

  Doctors Accuse NextSource Biotech for Hiking the Price on Key Cancer Drug Nine Times

  The cost of a vital cancer drug has gone up 15-fold in four years after its new owner hiked prices on nine separate occasions.

  December 28, 2017

   · 

  1 min read